JOURNAL OF ADVANCED HOMOEOPATHIC STUDIES (JAHS)

A Peer Reviewed International Platform for Homoeopathic Excellence

ISSN: 3139-1826 | ESTD: 2025 | Frequency: Quarterly | Open Access

Editor-in-Chief: Dr. Salini Mandal B.G. | Published by: AdvHom Society

ETHICAL CHALLENGES IN CONDUCTING PEDIATRIC HOMOEOPATHIC CLINICAL RESEARCH: A NARRATIVE REVIEW

Dr. Rakhi Sharma [1*], Dr. Amiya Nanda Dev Goswami [2], Dr. Tanay Vyas [3], Dr. Neelam Tiwari [4],

Article Type:	Review article
Timeline:	Received: [26-08-2026] | Revised: [15-09-2026] | Accepted: [16-09-2026] | Published: [21-09-2026]
Corresponding Author * email address	93drrakhi93@gmail.com
doi	https://doi.org/10.67062/jahs.v2.i3.4

[1]Post Graduate Scholar, PG Department of Paediatrics, Rajasthan Vidyapeeth Homoeopathic Medical College and Hospital, Udaipur Rajasthan

[2]Principal, Rajasthan Vidyapeeth Homoeopathic Medical College and Hospital, Udaipur Rajasthan

[3]Assistant Professor, PG Department of Paediatrics, Rajasthan Vidyapeeth Homoeopathic Medical College and Hospital, Udaipur Rajasthan

[4]Assistant Professor, PG Department of Practice of Medicine, Rajasthan Vidyapeeth Homoeopathic Medical College and Hospital, Udaipur Rajasthan

Corresponding Author* Details:

Dr. Rakhi Sharma
Post Graduate Scholar,
PG Department of Paediatrics,
Rajasthan Vidyapeeth Homoeopathic Medical College and Hospital,
Udaipur Rajasthan
Mail. Id: 93drrakhi93@gmail.com

ABSTRACT

Clinical research involving children is essential for improving pediatric healthcare, but it raises ethical concerns that are different from those encountered in adults. Children have developing cognitive and decision-making abilities and therefore require additional safeguards during research participation. At the same time, excluding children from research can result in inadequate evidence for interventions that are subsequently used in pediatric practice.

These considerations are particularly relevant to homoeopathic clinical research, where individualized prescribing, subjective symptom assessment, treatment modification and the use of individualized medicines can create additional methodological and ethical questions. The present narrative review discusses the major ethical challenges associated with pediatric homoeopathic clinical research, including vulnerability of children, informed consent, child assent, parental permission, risk-benefit assessment, privacy and confidentiality, compensation, ethics committee oversight, research in resource-limited settings and scientific integrity. International frameworks including the Declaration of Helsinki, CIOMS guidelines, ICH Good Clinical Practice and WHO guidance are considered alongside Indian requirements, particularly the ICMR National Ethical

Guidelines for Biomedical and Health Research Involving Human Participants and the ICMR National Ethical Guidelines for Biomedical Research Involving Children. The relevance of the 2025 ICMR addendum on Research in Integrative Medicine and the Good Clinical Practice Guidelines for Clinical Trials in homoeopathy is also discussed. Particular attention is given to placebo use, rescue treatment, individualized prescribing, outcome assessment and the need to avoid therapeutic misconception. Ethical pediatric homoeopathic research requires protection of the child's welfare together with adequate scientific rigor, transparency and responsible reporting.

Keywords: Pediatric Research, Homoeopathy, Research Ethics, Informed Consent, Child Assent, Clinical Trials, Vulnerable Population, ICMR, Good Clinical Practice

1. INTRODUCTION

Research involving children presents a basic ethical dilemma. Children need protection because they may not have the cognitive or legal capacity to make independent decisions about research participation. However, children also need evidence that is specifically relevant to their age group. Clinical findings obtained in adults cannot always be extrapolated directly to infants, children and adolescents because disease presentation, developmental physiology and treatment responses may differ. [1-4] The ICMR National Ethical Guidelines for Biomedical Research Involving Children recognize both sides of this problem. Children are particularly vulnerable to research-related harm but excluding them from research may prevent them from benefiting from advances in healthcare. [4] The ICMR guidelines therefore emphasize the need for appropriately designed pediatric research while requiring additional safeguards for children. [4] The ethical question, therefore, is not whether children should participate in research at all. The more relevant question is under what circumstances their participation is justified and how their rights and welfare can be protected.

This question becomes more complex in homoeopathic clinical research. Individualized prescribing may involve a detailed assessment of the child's symptoms and behavioral characteristics, followed by selection of a medicine according to a predefined or individualized therapeutic approach. The prescription may subsequently be modified according to clinical response. Such characteristics can be difficult to accommodate within conventional trial designs without compromising either the clinical model being investigated or the methodological requirements of the research. The Good Clinical Practice framework developed specifically for clinical trials in homoeopathy provides an important methodological reference in this context. [12] Ethical research must therefore address two responsibilities simultaneously. The first is protection of the child. The second is production of reliable knowledge. A study that exposes children to procedures but is incapable of answering its research question has limited ethical justification. Scientific validity is consequently an important component of ethical acceptability. [1,3,5]

2. LITERATURE SEARCH

A narrative literature search was conducted using PubMed, WHO, ICMR, CIOMS, World Medical Association and ICH resources, together with relevant Indian homoeopathic research and regulatory sources. The search focused on pediatric research ethics, informed consent, child assent, vulnerable populations, homoeopathy clinical research, homoeopathy clinical trials, Good Clinical Practice in homoeopathy and research ethics in complementary and traditional medicine. Priority was given to national and international ethical guidelines, pediatric-specific

recommendations and documents directly relevant to clinical research involving homoeopathy. As this was a narrative review, literature selection was based on clinical and academic relevance. No predefined date range or formal source-counting procedure was applied because the review was narrative in design and did not involve systematic-review screening or quantitative synthesis.

3. WHY CHILDREN ARE A VULNERABLE RESEARCH POPULATION

Children are considered vulnerable participants because their capacity for independent decision-making develops gradually. Their understanding of research, risk, randomization and uncertainty varies substantially with age and maturity. [4]

The ICMR pediatric guidelines specifically state that research involving children should take their physical, cognitive, emotional and psychosocial development into account. They also emphasize the need for additional protection because children cannot independently provide legally valid consent in the same manner as competent adults. [4]

Vulnerability is not, however, synonymous with incapacity.

An adolescent may understand the purpose of a study and its potential consequences much better than a young child. Similarly, a chronically ill child may have considerable experience with healthcare procedures and may be able to express meaningful preferences.

This is why contemporary pediatric research ethics emphasizes additional protection rather than automatic exclusion. The Declaration of Helsinki also recognizes the need for special protection of vulnerable individuals and groups while acknowledging that exclusion from research may itself result in inequity. [1]

There is another important problem. Excessive exclusion of children from research can leave clinicians with inadequate pediatric evidence and may result in children receiving interventions that have primarily been studied in adults. Ethical pediatric research must therefore balance the risks of participation against the risks of continuing to treat children in the absence of appropriate evidence. [3,4]

4. HISTORICAL EVOLUTION OF PEDIATRIC RESEARCH ETHICS

The development of research ethics has been influenced by serious violations of human rights in medical research. The Nuremberg Code, the Declaration of Helsinki and subsequent international guidelines established principles concerning voluntary participation, risk minimization, scientific justification and independent ethical oversight. [1,3]

These international developments subsequently influenced national ethical frameworks, with countries adapting general principles of autonomy, risk minimization, scientific validity and independent ethical review to their own legal, cultural and healthcare contexts. In India, these principles were progressively incorporated into ICMR ethical guidance and were subsequently supplemented by pediatric-specific recommendations.

Pediatric research subsequently developed its own safeguards because children have particular vulnerabilities. In India, the ICMR initially developed ethical guidance for biomedical research in 1980, followed by revisions in 2000, 2006 and 2017. A separate document dealing specifically with biomedical research involving children was developed because the general guidelines did not adequately address all pediatric-specific situations. [4]

The historical experience also demonstrated that protecting children through complete exclusion can have unintended consequences. If pediatric studies are not conducted, children may become dependent on evidence generated in adults. Ethical pediatric research consequently attempts to avoid both extremes: unnecessary experimentation and unnecessary exclusion. [3,4]

5. CORE ETHICAL PRINCIPLES

5.1 Autonomy

Autonomy refers to respect for an individual's capacity to make decisions concerning participation in research. [1,3]

In young children, autonomy is limited by developmental and legal considerations. For this reason, pediatric autonomy is usually protected through parental or legally authorized permission together with developmentally appropriate participation of the child in the decision. [4]

Respect for autonomy also requires honest communication. Parents should understand whether the study is observational or interventional, whether treatment allocation is randomized, whether a placebo is involved, what additional procedures will be performed and what alternatives are available. [1,3]

In homoeopathic research, this becomes particularly important because parents may already have strong expectations about the treatment system. The research team should distinguish clearly between clinical care and the uncertainty that exists when an intervention is being evaluated as part of research.

5.2 Beneficence

Beneficence requires researchers to pursue a meaningful scientific and clinical objective while seeking to maximize potential benefit. [1,3]

The ICMR pediatric guidelines emphasize that research involving children should be scientifically justified and should not expose them to undue harm. [4]

In pediatric homoeopathic research, beneficence includes appropriate clinical assessment, competent supervision, monitoring of treatment response and prompt management of deterioration.

A trial should also have a realistic prospect of generating useful information. A scientifically weak study cannot be justified merely because the intervention itself is considered low risk. [3,5]

5.3 Non-maleficence

The principle of non-maleficence requires investigators to minimize avoidable harm. [1,3]

Risk assessment should focus on what the child experiences because of research participation in addition to routine clinical care. The ICMR pediatric guidelines specifically provide a framework for classifying pediatric research according to the level of risk involved. [4]

For a pediatric homoeopathic study, the protocol should therefore identify:

- Research-specific procedures;
- Expected discomforts;
- Possible adverse events;
- Criteria for treatment discontinuation;
- Criteria for withdrawal;
- Rescue treatment;
- Emergency referral;
- Management of serious adverse events.

A low expected pharmacological risk does not eliminate all ethical risk. Delayed diagnosis, delayed referral or withholding clinically indicated treatment can cause greater harm than the intervention itself.

5.4 Justice

Justice concerns fair selection of research participants and fair distribution of the burdens and potential benefits of research. [1,3]

Children from economically disadvantaged families should not be recruited simply because they are readily available or because financial incentives may influence parental decisions. The ICMR pediatric guidelines specifically address the risk of undue influence and financial inducement in vulnerable populations. [4]

Justice is also relevant to the choice of research question. Research resources are limited, and studies should address clinically meaningful questions rather than simply selecting populations that are convenient to recruit.

WHO guidance on research priority setting similarly recognizes that deciding which health

research should be undertaken has ethical implications because available resources and potential benefits are limited. [11]

6. INTERNATIONAL ETHICAL FRAMEWORKS

6.1 Declaration of Helsinki

The Declaration of Helsinki remains one of the central international documents governing medical research involving human participants. The current official version was adopted by the World Medical Association in October 2024. [1]

The Declaration emphasizes scientific and ethical justification, appropriate risk-benefit assessment, protection of vulnerable populations, informed consent, privacy and confidentiality, independent ethics review and responsible dissemination of results. [1]

For pediatric research, the principles concerning individuals who cannot provide legally valid consent are particularly important. Parental or legally authorized permission is required when appropriate, while the child's developing ability to participate in decisions should also be respected. [1]

6.2 CIOMS

The Council for International Organizations of Medical Sciences, in collaboration with WHO, published the fourth edition of the *International Ethical Guidelines for Health-related Research Involving Humans* in 2016. [2] CIOMS places particular emphasis on the scientific and social value of research, vulnerable populations, research in low-resource settings, informed consent, use of biological samples and health-related data. [2] These considerations are relevant to pediatric homoeopathic research conducted in communities where literacy, healthcare access and socioeconomic conditions may influence participation.

6.3 ICH Good Clinical Practice

The revised framework emphasizes quality by design and proportionate, risk-based approaches to trial conduct. The ICH E6(R3) Annex 2, adopted in 2026, provides additional considerations for certain trial designs, including pragmatic and decentralized approaches, with implementation scheduled according to applicable regulatory jurisdictions [7, 8]

For homoeopathic research, ICH GCP should be applied according to the scope of the study and applicable Indian requirements rather than being treated as a substitute for national ethical or regulatory guidance.

6.4 WHO

WHO considers ethics review an essential part of research involving human participants. Its guidance emphasizes protection of dignity, rights and welfare and provides standards for ethics committees responsible for reviewing and overseeing health research. [9]

The WHO guidance also provides practical standards for the constitution and functioning of research ethics committees and emphasizes independent ethical review before and during research. [9].

WHO benchmarking tools can additionally support assessment of the functioning and oversight capacity of research ethics committees. [10]

6.5 ICMR

For research conducted in India, the ICMR National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, 2017, provide the principal national ethical framework. The guidelines address ethical review, informed consent, vulnerable populations, privacy, confidentiality, compensation, responsible conduct of research and continuing review. [3]

The pediatric-specific ICMR guidelines provide additional guidance on risk classification, assent, confidentiality, compensation and special situations such as neonatal research. [4].

7. KEY ETHICAL SAFEGUARDS IN PEDIATRIC RESEARCH

7.1 Informed Consent

In pediatric research, informed consent is generally obtained from the parent or legally

authorized representative. However, consent should not be treated as a form that simply requires a signature. [3,4]

The ICMR pediatric guidelines describe consent as an ongoing process. Parents and children, according to their developmental ability, should understand what participation involves and should have opportunities to ask questions. [4]

The information provided should include:

- Purpose of the study.
- Study procedures.
- Duration of participation.
- Possible risks and discomforts.
- Potential benefits.
- Available alternatives.
- Confidentiality arrangements.
- Voluntary nature of participation.
- Right to withdraw.
- Management of research-related injury.
- Compensation arrangements.
- Contact details for questions or complaints.

The language used should be appropriate for the educational and linguistic background of the family. Technical and legal terminology that is difficult for parents to understand should be avoided. [4]

This is particularly important in pediatric homoeopathic studies because parents may interpret individualized treatment as evidence that the investigator has selected the intervention specifically for their child's benefit. The research team should explain that participation is intended to generate knowledge and that direct benefit cannot always be guaranteed. This helps reduce therapeutic misconception. [4]

7.2 Child Assent

Child assent provides an opportunity for children to participate in decisions about their own research participation.

The ICMR defines assent as affirmative agreement to participate. Simply failing to object does not constitute assent. The process should take account of the child's developmental level, maturity, reading ability and social and cultural context. [4]

The Indian pediatric guidance provides age-specific recommendations. For children aged 7 to 11 years, oral assent should be obtained in the presence of the parent or legally authorized representative. For children aged 12 to 18 years, written assent is recommended in addition to parental or legal representative consent. Children below 7 years generally require parental consent rather than formal assent. [4]

The process should nevertheless remain developmentally sensitive. A 15-year-old should receive substantially more information than a young child, and assent may need to be revisited in a long-term study as the child matures. [4]

7.3 Role Of Parents and Legal Guardians

Parents or legally authorized representatives play a central role in pediatric research because they provide permission on behalf of the child when the child cannot legally provide consent. [3,4]

Parental permission, however, does not remove the investigator's responsibility to protect the child. The investigator must still determine whether participation is appropriate, whether the risks are justified and whether the child is showing signs of distress or refusal.

The possibility of therapeutic misconception should also be addressed. Parents may understand research as a form of enhanced treatment rather than as an investigation designed primarily to generate generalizable knowledge. The ICMR specifically identifies this misunderstanding as an important concern during pediatric consent. [4].

7.4 Risk-Benefit Assessment

Risk assessment is one of the most important parts of pediatric research ethics. [3,4]

The ICMR pediatric guidelines broadly classify research as:

1. Less than minimal risk;
2. Minimal risk;

3. Minor increase over minimal risk or low risk; and
4. More than minimal or high risk. [4]

Minimal-risk procedures may include history taking, physical examination and anthropometry when performed appropriately. Blood sampling may represent a minor increase over minimal risk, while substantially invasive procedures may fall into higher-risk categories. [4]

For homoeopathic studies, risk assessment should cover more than the medicine being tested. Investigators should also consider the consequences of delayed treatment, unnecessary investigations, placebo use, repeated visits, loss to follow-up and failure to recognize clinical deterioration. This distinction is especially important in acute pediatric illnesses. A study of an intervention for mild, self-limiting symptoms raises different ethical concerns from a study involving sepsis, severe dehydration, respiratory distress or other potentially life-threatening conditions.

7.5 Privacy and Confidentiality

Children have a right to privacy even when their parents provide permission for participation. [1,3,4]

The ICMR pediatric guidelines place particular importance on confidentiality because children may have limited ability to understand or challenge inappropriate disclosure of their information. [4]

Pediatric homoeopathic research may include information about:

- Developmental history;
- Behavior;
- Emotional symptoms;
- Family history;
- School performance;
- Socioeconomic circumstances;
- Photographs;
- Audio or video recordings;
- Individualized symptom descriptions.

Identifiable information should therefore be coded where possible, access should be restricted to authorized personnel and publication should avoid unnecessary identification of individual children.

7.6 Data Protection and Storage

Data protection begins at the design stage of a study.

The protocol should specify how participant information will be collected, coded, stored and eventually destroyed or archived. Where electronic systems are used, investigators should consider password protection, access control, backup arrangements and the possibility of unauthorized disclosure.

The ICMR pediatric guidelines provide requirements for appropriate record retention and confidentiality of research documentation. [4]

Future use of biological samples or identifiable data should also be addressed prospectively rather than assuming that the original consent automatically covers all future research. [2,3]

7.7 Compensation for Participation and Research-Related Injury

Children and their caregivers should not be required to bear expenses generated by research participation. Reasonable reimbursement, such as travel-related expenses, may be appropriate. However, payments should not become an inducement to participate or remain in the study. The ICMR pediatric guidelines specifically caution against excessive financial incentives, particularly where families have limited economic resources. [4]

Research-related injury is a separate issue. The ICMR guidelines recognize financial compensation and/or other assistance for temporary or permanent impairment resulting from research participation, subject to the applicable requirements. [4]

The protocol and participant information sheet should therefore explain the arrangements for managing and compensating research-related injury.

7.8 Ethics Committee Responsibilities

Ethics committees have responsibilities that extend well beyond reviewing the consent form. The ICMR states that research involving human participants should undergo ethical review before initiation and that ethics committees have continuing responsibility for monitoring approved research. They should assess both the scientific quality and ethical implications of the proposed methodology. [3]

For pediatric homoeopathic research, the Ethics Committee should examine:

- Scientific rationale;
- Study design;
- Sample size;
- Eligibility criteria;
- Intervention and comparator;
- Benefit-risk assessment;
- Consent and assent procedures;
- Investigator qualifications;
- Clinical facilities;
- Rescue-treatment provisions;
- Adverse-event reporting;
- Data protection;
- Compensation;
- Conflicts of interest;
- Plans for publication.

Continuing review should consider serious adverse events, protocol deviations, new safety information and progress reports. Where significant ethical non-compliance occurs, corrective action or suspension of the study may be necessary. [3]

WHO similarly emphasizes independent ethics review as an essential component of research involving humans. [9]

7.9 Ethical Challenges in Low-Resource Settings

Research conducted in resource-limited settings may face additional challenges.

The ICMR pediatric guidelines identify low parental literacy, misunderstanding of research, financial inducement and inequitable distribution of research burdens as important concerns. [4]

In these circumstances, parents may perceive participation as a way to obtain treatment that would otherwise be inaccessible. The distinction between research and clinical care can consequently become blurred.

Investigators should use understandable local-language information, provide sufficient time for discussion, avoid excessive financial incentives and make it clear that refusal to participate will not compromise routine clinical care.

The research question should also have relevance to the population from which participants are recruited. CIOMS specifically emphasizes the ethical importance of social value, fair distribution of benefits and burdens, and appropriate safeguards in low-resource settings. [2]

8. ETHICAL CHALLENGES SPECIFIC TO PEDIATRIC HOMOEOPATHIC RESEARCH

8.1 Individualized prescribing and reproducibility

One of the most distinctive methodological issues in homoeopathic clinical research is individualized prescribing.

In routine clinical practice, the medicine may be selected according to the patient's individual symptom picture rather than solely according to the diagnostic label. During a research study, however, the process needs to be sufficiently described to allow investigators and readers to understand how treatment decisions were made. [12]

A protocol investigating individualized homoeopathic treatment should therefore define, as far as possible:

- The case-taking procedure;
- The symptoms considered relevant;
- Repertorial or other decision-making methods;
- Criteria for remedy selection;
- Rules for repetition;
- Circumstances in which the prescription may be changed;

- Documentation of changes during follow-up.

Without such documentation, it becomes difficult to determine whether differences in outcome are related to the intervention or to variations in treatment decisions.

8.2 Treatment modification during a trial

Treatment modification raises an additional ethical issue.

A child who is not improving should not be maintained on an ineffective intervention merely because changing the treatment could affect the research outcome. At the same time, frequent unscheduled changes may make interpretation of the study difficult.

The most appropriate solution is to establish rules in the protocol before recruitment begins.

For example, the protocol may define when treatment can be changed, who is authorized to make the decision, how the reason for the change will be recorded and how such participants will be included in the final analysis.

This approach protects both the child and the scientific integrity of the study. [7,12]

8.3 Placebo-Controlled Studies

Placebo-controlled research can provide valuable information about treatment effects, but its use in children requires particular caution.

The ethical acceptability of placebo depends partly on the disease being studied and on the availability of effective treatment. In a mild, self-limiting condition, the risk may be different from that in a disease where delay in effective therapy could result in serious or irreversible harm.

The Declaration of Helsinki places restrictions on placebo use when withholding an established effective intervention would expose participants to additional risks of serious harm. [1]

Therefore, placebo-controlled homoeopathic studies involving children should include clear criteria for rescue treatment and withdrawal.

8.4 Rescue Treatment

Rescue treatment is particularly important in pediatric acute-care research.

A study should specify what constitutes treatment failure and what clinical findings require escalation of care. Depending on the condition, these may include worsening dehydration, persistent respiratory distress, altered consciousness, persistent high fever with concerning features, inability to tolerate oral intake or other predefined clinical indicators.

The decision to provide necessary conventional treatment should never be delayed merely to preserve adherence to the research protocol.

The protocol should therefore specify rescue treatment in advance rather than leaving the decision entirely to an investigator's discretion during an emergency. This is consistent with the broader principles of participant protection and risk minimization described in GCP and pediatric research guidance. [4,7]

8.5 Objective Outcome Assessment

The credibility of pediatric homoeopathic research depends heavily on how outcomes are measured.

Terms such as "improved", "better", "marked improvement" or "constitutional improvement" may be clinically meaningful in some contexts, but they are difficult to interpret unless clearly defined.

Where possible, researchers should use validated or objectively measurable outcomes appropriate to the condition. These may include symptom duration, disease severity scores, frequency of clinical events, treatment failure, hospitalization, quality-of-life measures or laboratory outcomes when clinically indicated.

Subjective outcomes can still be studied, particularly where patient-reported or caregiver-reported symptoms are important, but the method of collection should be standardized.

This is not simply a statistical issue. Reliable outcome measurement determines whether the study can generate interpretable evidence and therefore relates directly to the ethical

justification for exposing children to research procedures. [1,7]

8.6 Hering's Law of Cure and Clinical Assessment

Hering's Law of Cure is a traditional homoeopathic concept used by some practitioners to interpret the direction and sequence of symptom change during treatment. [13] In clinical research, however, such interpretation should not replace predefined and clinically meaningful criteria for improvement, deterioration or treatment failure. Changes in symptoms should therefore be documented prospectively using standardized outcome measures and clinical assessment. Where a change is interpreted according to the concept of Hering's Law, the interpretation should be clearly distinguished from objective evidence of clinical improvement and should not delay rescue treatment or referral when clinically indicated.

8.7 Concomitant Treatment

Pediatric homoeopathic studies should clearly state which supportive and conventional treatments are permitted.

For example, in an acute gastrointestinal illness, hydration and nutritional support remain clinically important. In a respiratory illness, oxygen or other emergency management may become necessary. Such care should not be withheld simply because it might influence the outcome of the homoeopathic intervention.

The protocol should therefore distinguish between the intervention under investigation and necessary supportive or rescue care. Participant welfare should remain the overriding consideration. [1,4,7]

8.8 Adverse-Event Reporting

A medicine being traditionally regarded as low risk does not eliminate the need for adverse-event surveillance.

Investigators should record new symptoms, worsening disease, suspected treatment-related reactions, allergic reactions, hospitalization, emergency interventions and treatment discontinuation.

The purpose of safety reporting is not to assume that the intervention caused every new symptom. Rather, it is to ensure that potentially important events are systematically documented and assessed. Good Clinical Practice requires appropriate safety monitoring and reliable documentation of clinical trial data. [7,12]

8.9 Homoeopathic Aggravation and Adverse Events

In homoeopathic clinical research, investigators may encounter the concept of homoeopathic aggravation, traditionally described as a temporary intensification of existing symptoms following administration of a medicine. However, this concept should not be used to automatically classify worsening symptoms as a therapeutic response.

From a research ethics and patient-safety perspective, any new, severe, persistent or clinically concerning symptom, deterioration of the underlying condition or unexpected clinical event should be assessed as a potential adverse event and managed according to the study protocol. The investigator should document the event, assess its temporal relationship and clinical significance, and determine whether treatment modification, discontinuation, rescue treatment or referral is required.

Thus, a proposed homoeopathic aggravation should be distinguished from an adverse event on the basis of systematic clinical assessment rather than assumption. In pediatric research, genuine deterioration must always take priority over preservation of the intended therapeutic interpretation.

8.10 Therapeutic Misconception in Homoeopathic Trials

Therapeutic misconception may be particularly relevant when parents believe that participation provides access to individualized treatment specifically selected for their child.

The consent process should explain the difference between clinical treatment intended primarily for the individual patient and research intended to answer a question that may benefit future patients.

The ICMR pediatric guidance specifically recognizes the possibility that parents may misunderstand the purpose of research and believe that participation is primarily intended to provide treatment. [4]

This distinction is particularly important when the intervention is individualized, because the individualized nature of the prescription may unintentionally strengthen the impression that the research intervention is necessarily the best treatment for that particular child.

For example, during the informed consent process, an investigator should explain that although an individualized homoeopathic medicine may be selected according to the child's symptom profile, the medicine is being evaluated as part of research and its effectiveness cannot be guaranteed for that individual child. Parents should also be informed that participation is voluntary and that necessary conventional or supportive treatment will not be withheld if the child's clinical condition requires it.

9. SYNTHESIS AND DISCUSSION

Ethical challenges in pediatric homoeopathic clinical research cannot be considered independently of methodological quality. The vulnerability of children requires appropriate parental permission and developmentally appropriate assent, but these safeguards are meaningful only when the research question has scientific and social value. Similarly, a low expected pharmacological risk does not eliminate ethical concerns when delayed diagnosis, delayed referral, inadequate rescue treatment or unreliable outcome assessment may affect the child's welfare.

Individualized prescribing creates a particular methodological challenge because treatment decisions may change according to the child's evolving symptom picture. This can be ethically acceptable only when the decision-making process, criteria for modification and rescue treatment are predefined and documented. Objective and reproducible outcome assessment is therefore important for distinguishing genuine clinical change from subjective interpretation.

In pediatric homoeopathic research, ethical acceptability ultimately depends on maintaining an appropriate balance between protection of the child and generation of scientifically credible evidence. Participant welfare should remain the overriding consideration, and necessary supportive, conventional or emergency treatment should never be withheld merely to preserve adherence to a research protocol.

10. HOMOEOPATHIC GOOD CLINICAL PRACTICE IN THE INDIAN CONTEXT

The Central Council for Research in Homoeopathy has published **Good Clinical Practice Guidelines for Clinical Trials in homoeopathy**, providing a homoeopathy-specific framework for clinical research. [12]

These guidelines should be considered alongside broader principles of research ethics and Good Clinical Practice rather than as a replacement for national ethical requirements.

The ICMR's 2025 **Ethical Requirements for Research in Integrative Medicine** should be understood separately. The document addresses research involving multimodal interventions in which AYUSH practices or modalities are integrated with conventional medicine. It recommends involvement of relevant AYUSH subject experts in ethics review and emphasizes that general Indian ethical requirements continue to apply. [6]

Therefore, a standalone pediatric homoeopathic clinical study should not automatically be described as an "integrative medicine" study. The applicable ethical and regulatory framework

depends on the actual study design and intervention.

For research involving homoeopathy in India, investigators should consider, as applicable:

- ICMR National Ethical Guidelines;
- ICMR pediatric research guidance;
- applicable regulatory requirements;
- Good Clinical Practice Guidelines for Clinical Trials in homoeopathy;
- institutional Ethics Committee requirements;
- Clinical Trials Registry-India requirements where applicable. [3,4,6,12].

11. SCIENTIFIC INTEGRITY AS AN ETHICAL RESPONSIBILITY

Research ethics continues after the last participant completes follow-up.

Fabrication, falsification, selective reporting and plagiarism can compromise the scientific record and may ultimately affect patient care. ICMR identifies fabrication, falsification and plagiarism as forms of research misconduct and emphasizes responsible research and publication practices. [14]

This is particularly important for homoeopathic research because the evidence base is frequently debated. Investigators should therefore be careful to distinguish:

- observed findings from interpretation;
- association from causation;
- exploratory findings from confirmatory evidence;
- statistical significance from clinical significance.

Negative or inconclusive results should be reported rather than selectively emphasizing favorable outcomes. Selective reporting can produce a misleading impression of treatment effectiveness and undermines the social value of research. [1,7,14]

A study should also avoid changing its primary outcome after examining the data unless such a change is transparently documented and appropriately justified.

12. FUTURE DIRECTIONS

Future pediatric homoeopathic research would benefit from greater methodological consistency without losing the clinical features that researchers intend to investigate.

1. Training in research ethics: Researchers should receive formal training in pediatric research ethics, Good Clinical Practice, informed consent, adverse-event reporting and biostatistics.

2. Documentation of individualized prescribing: Individualized prescribing should be documented in sufficient detail to make the intervention understandable and reproducible.

3. Objective outcome assessment: Pediatric studies should increasingly use validated outcome measures and, where feasible, independent outcome assessment.

4. Predefined rescue treatment: Rescue treatment and treatment-failure criteria should be specified before recruitment begins.

5. Clinical trial registration: Clinical trial registration and prospective protocol documentation should become routine for applicable interventional studies.

6. Responsible publication: Research findings should be reported accurately irrespective of whether they support the original hypothesis. [7,14]

13. LIMITATIONS OF THE REVIEW

This article is a narrative review and not a systematic review or meta-analysis. The literature and guidance documents were selected to provide an overview of ethical issues relevant to pediatric clinical research, with particular attention to Indian requirements and homoeopathic research. Consequently, the selection of literature may be influenced by author judgment, and the review should not be considered an exhaustive synthesis of every publication concerning pediatric research ethics.

14. CONCLUSION

Ethical pediatric homoeopathic research requires more than obtaining parental consent and approval from an Ethics Committee. The entire research process must be designed around the welfare of the child.

Children require additional protection because their capacity for independent decision-making develops gradually. At the same time, excluding them from research can leave important pediatric questions unanswered. A reasonable ethical approach is therefore to include children only when the research question is relevant to them, the study is scientifically sound and the anticipated risks are appropriately controlled. [1,3,4]

In homoeopathic clinical research, additional issues arise from individualized prescribing, treatment modification, subjective symptom assessment, placebo use and the management of clinical deterioration. These issues need to be addressed prospectively in the protocol rather than being resolved informally during the study. [7,12]

The ethical framework should combine the principles of autonomy, beneficence, non-maleficence and justice with pediatric-specific safeguards for consent, assent, confidentiality, risk assessment and compensation. International guidance from the Declaration of Helsinki, CIOMS, WHO and ICH provides a broader framework, while Indian studies must also comply with applicable ICMR, regulatory, institutional and homoeopathy-specific requirements. [1-7,9,12]

Ultimately, the quality of pediatric homoeopathic research depends on two things that cannot be separated: protecting the child who participates and producing evidence that can be trusted.

15. FUNDING

No external funding was received for this work.

16. REFERENCES

1. World Medical Association. **Declaration of Helsinki: ethical principles for medical research involving human participants.** Ferney-Voltaire: World Medical Association; 2024.
2. Council for International Organizations of Medical Sciences. **International ethical guidelines for health-related research involving humans.** 4th ed. Geneva: CIOMS; 2016. doi:10.56759/rgxl7405.
3. Indian Council of Medical Research. **National Ethical Guidelines for Biomedical and Health Research Involving Human Participants.** New Delhi: Indian Council of Medical Research; 2017.
4. Indian Council of Medical Research. **National Ethical Guidelines for Biomedical Research Involving Children.** New Delhi: Indian Council of Medical Research; 2017.
5. Indian Council of Medical Research. **Handbook on National Ethical Guidelines for Biomedical and Health Research Involving Human Participants.** New Delhi: Indian Council of Medical Research; 2018.
6. Indian Council of Medical Research. **Ethical Requirements for Research in Integrative Medicine: an addendum to ICMR National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, 2017.** New Delhi: Indian Council of Medical Research; 2025.
7. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. **ICH E6(R3) guideline for good clinical practice.** Geneva: ICH; 2025. The current Principles and Annex 1 became effective in the EU on 23 July 2025; Annex 2 was adopted at Step 4 in June 2026 and has a later implementation date.
8. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. **ICH E6(R3) guideline for good clinical practice: Annex 2.** Geneva: ICH; 2026.
9. World Health Organization. **Standards and operational guidance for ethics review of health-related research with human participants.** Geneva: World

Health Organization; 2011. ISBN:9789241502948.
10. World Health Organization. **WHO tool for benchmarking ethics oversight of health-related research involving human participants.** Geneva: World Health Organization; 2023.
11. World Health Organization. **WHO guidance on the ethics of health research priority setting.** Geneva: World Health Organization; 2025.
12. Central Council for Research in Homoeopathy. **Good Clinical Practice Guidelines for Clinical Trials in Homoeopathy.** New Delhi: Ministry of AYUSH; 2021.
13. Brien SB, Harrison H, Daniels J, Lewith G. Monitoring improvement in health during homeopathic intervention. Development of an assessment tool based on Hering's Law of Cure: the Hering's Law Assessment Tool (HELAT). Homeopathy. 2012;101(1):28-37. doi:10.1016/j.homp.2011.10.002.
14. Indian Council of Medical Research. **ICMR Policy on Research Integrity and Publication Ethics (RIPE).** New Delhi: Indian Council of Medical Research; 2019.